Trial Search Results

CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy

This study assesses computed tomography (CT) perfusion imaging in predicting treatment response in patients with non-small cell lung cancer or tumors that have spread from the primary site (place where it started) to the lungs (metastases) treated with stereotactic ablative radiation therapy. CT perfusion imaging is a special type of CT that uses an injected dye in order to see how blood flow through tissues, including lung tissue. CT perfusion imaging of the lungs may help doctors learn whether perfusion characteristics of lung tumors may be predictive of response to treatment and whether lung perfusion characteristics can be used to follow response to treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Device: CAPP-Seq
  • Drug: Isovue-200
  • Radiation: Computed Tomography Perfusion Imaging


Phase 1


Inclusion Criteria:

   - Patients undergoing SABR for the treatment of a lung tumor, inclusive of non-small
   cell lung cancer or lung metastases

Exclusion Criteria:

   - Patients who are pregnant or are trying to become pregnant are excluded from this

   - Patients with renal failure, defined as glomerular filtration rate (GFR) < 60 at the
   time of the radiation treatment-planning (RTP) scan, will be excluded

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Samantha Wong